Literature DB >> 26447521

Biomarkers of cellular apoptosis and necrosis in donor myocardium are not predictive of primary graft dysfunction.

O Szarszoi1, J Besik, M Smetana, J Maly, M Urban, J Maluskova, A Lodererova, L Hoskova, Z Tucanova, J Pirk, I Netuka.   

Abstract

Primary graft dysfunction (PGD) is a life-threatening complication among heart transplant recipients and a major cause of early mortality. Although the pathogenesis of PGD is still unclear, ischemia/reperfusion injury has been identified as a predominant factor. Both necrosis and apoptosis contribute to the loss of cardiomyocytes during ischemia/reperfusion injury, and this loss of cells can ultimately lead to PGD. The aim of our prospective study was to find out whether cell death, necrosis and apoptosis markers present in the donor myocardium can predict PGD. The prospective study involved 64 consecutive patients who underwent orthotopic heart transplantation at our institute between September 2010 and January 2013. High-sensitive cardiac troponin T (hs-cTnT) as a marker of minor myocardial necrosis was detected from arterial blood samples before the donor's pericardium was opened. Apoptosis (caspase-3, active + pro-caspase-3, bcl-2, TUNEL) was assessed from bioptic samples taken from the right ventricle prior graft harvesting. In our study, 14 % of transplant recipients developed PGD classified according to the standardized definition proposed by the ISHLT Working Group. We did not find differences between the groups in regard to hs-cTnT serum levels. The mean hs-cTnT value for the PGD group was 57.4+/-22.9 ng/l, compared to 68.4+/-10.8 ng/l in the group without PGD. The presence and severity of apoptosis in grafted hearts did not differ between grafts without PGD and hearts that subsequently developed PGD. In conclusion, our findings did not demonstrate any association between measured myocardial cell death, necrosis or apoptosis markers in donor myocardium and PGD in allograft recipients. More detailed investigations of cell death signaling pathways in transplanted hearts are required.

Entities:  

Mesh:

Year:  2015        PMID: 26447521     DOI: 10.33549/physiolres.933105

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  4 in total

1.  Elevated Troponin? Take Heart and Reconsider!

Authors:  Shravani Pasupneti; Kiran Khush
Journal:  Circ Heart Fail       Date:  2016-06       Impact factor: 8.790

2.  Cardiac Graft Assessment in the Era of Machine Perfusion: Current and Future Biomarkers.

Authors:  Martina Bona; Rahel K Wyss; Maria Arnold; Natalia Méndez-Carmona; Maria N Sanz; Dominik Günsch; Lucio Barile; Thierry P Carrel; Sarah L Longnus
Journal:  J Am Heart Assoc       Date:  2021-01-30       Impact factor: 5.501

Review 3.  Donor Cardiac Troponin for Prognosis of Adverse Outcomes in Cardiac Transplantation Recipients: a Systematic Review and Meta-analysis.

Authors:  Zhengyang Liu; Luke A Perry; Jahan C Penny-Dimri; Michael Handscombe; Isabella Overmars; Mark Plummer; Reny Segal; Julian A Smith
Journal:  Transplant Direct       Date:  2021-12-13

Review 4.  Programmed necrosis in cardiomyocytes: mitochondria, death receptors and beyond.

Authors:  Junxia Zhang; Dairu Liu; Mao Zhang; Yan Zhang
Journal:  Br J Pharmacol       Date:  2018-06-25       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.